V. M. Filippova
A5067240684- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Stress, Anesthesia, and Immune Response
- Genetic factors in colorectal cancer
- Cancer, Lipids, and Metabolism
- Advanced Breast Cancer Therapies
- Renal cell carcinoma treatment
- Endometriosis Research and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
Moscow City Oncology Hospital №62
2022-2025
Regional Cancer Center
2019
Introduction : The systemic therapy of patients with metastatic luminal HER2‑negative breast cancer (mBC) in‑ cludes various options, which can be fundamentally divided into endocrine and chemotherapy. According to the Clinical Guidelines, both international Russian, “gold standard” 1st line for is a combination cyclindependent kinase inhib‑ itors 4 / 6 (iCDK4 6) (ET). However, until recently we did not have complete data on characteristics Russian population HER2‑breast cancer, their...
Aim . To assess the efficacy and safety of lenvatinib pembrolizumab for treatment mismatch repair-proficient endometrial cancer (EC) in routine clinical practice Russia. Materials methods This multicenter, retrospective, cohort study included patients with recurrent metastatic EC from 37 centers Russia treated between May 2020 April 2023. Patients histologically verified without microsatellite instability who received ≥1 course pembrolizumab/lenvatinib therapy were study. The primary...
Introduction. The multikinase inhibitors have demonstrated high clinical efficacy in treatment of the radioiodine refractory differentiated thyroid cancer. At same time, inclusion criteria studies has reflected a minimum set characteristics important for beginning use these drugs and an approach that takes into account tumor progression rate (the volume doubling time) absence manifestations disease made it possible to individualize start therapy. Aim. To describe evaluate barriers drivers...
Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead long-term and delayed effects compared chemotherapy. Estimation of efficacy quality life are crucial when we talking about in whole. Aim. To evaluate the clinical lenvatinib plus pembrolizumab patients with EC. Materials methods . The study included 43 stages I-IV EC mismatch repair-proficient tumors duration more than 9 months. We evaluated median progression-free survival, objective...
Aim. To assess the efficacy and safety of lenvatinib plus pembrolizumab for treatment mismatch repair-proficient (pMMR) endometrial cancer (EC) in routine clinical practice Russia. Materials methods. This multicenter, retrospective, cohort study included 114 patients with recurrent metastatic EC from 37 centers Russia treated between December 2020 November 2024. Patients histologically verified without microsatellite instability were included. The primary endpoint was progression-free...
Background. Hepatocellular carcinoma (HCC) (hepatocarcinoma) is the most common (about 85% of cases) malignant liver tumor originating from hepatocytes. According to officially published statistics for city Moscow 2019,329 people were registered with first-ever diagnosed C22 neoplasms (liver and intrahepatic bile ducts, including 6.7% those who actively identified. The absolute number such patients at end year was 716, which 5.7 per 100 000 population. contingent accumulation index 2.2 (the...
Aim. To determine lenvatinib treatment outcomes in patients with advanced unresectable hepatocellular carcinoma (uHCC) real clinical practice. Patients and methods. A multicenter retrospective observational study included 58 a confirmed uHCC diagnosis receiving lenvatinib. At baseline, ECOG, Child-Pugh BCLC scores were assessed. The objective response rate (ORR), disease control (DCR), median overall survival (OS) progression-free (PFS) rates In addition, adverse effects (AE) during...
Introduction . The randomized MPACT study showed that nab-paclitaxel plus gemcitabine results in statistically significantly longer life expectancy. objective of this retrospective is to obtain relevant data on the efficacy combination real clinical practice Russia. Materials and methods included patients with morphologically proven locally advanced or metastatic pancreatic cancer, a general condition assessed ECOG scale between 0-2, which received nab-paclitaxel. Immediate long-term...